In the first part of a two-part interview, Mann discusses the state of technology in proteomics and what still needs to get done for proteomics to cross to the clinical side.
Millipore is betting that the buy, which is expected to close in the next several weeks, will provide its customers a powerful cell biology/protein expression-analysis tool for the benchtop.
Without specific guidance from the FDA regarding KRAS testing, drugmakers Bristol-Myers Squibb and Amgen are facing lower sales of their colorectal cancer drugs Erbitux and Vectibix, and may need to get creative in how they market their drugs to patients and doctors.
Once a tool that only piqued the interest of technology developers, protein microarrays have come into their own as scientists find new ways to apply them in basic and translational studies.
Small (and not-so-small) noncoding RNAs have thrown a spanner in the works of understanding genome function. We take a look at the major questions brought about by micro-RNA, Piwi-interacting RNA, and more.
